Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Hodgkin Disease 5Lymphoma 4Recurrence 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Uveal Melanoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Glioblastoma 2Burkitt Lymphoma 2Vasculitis, Central Nervous System 1Stiff-Person Syndrome 1Rasmussen subacute encephalitis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Plasmablastic Lymphoma 1Pediatric Brain Tumor 1Pancreatic Neoplasms 1Opsoclonus-Myoclonus Syndrome 1Oligodendroglioma 1Neuromyelitis Optica 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Cyclophosphamide 13Prednisone 10N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Doxorubicin 9Vincristine 8Azacitidine 6romidepsin 5Gemcitabine 5Brentuximab Vedotin 5fludarabine 4Etoposide 4Dexamethasone 4pembrolizumab 3belinostat 3Lenalidomide 3Biopsy 310-propargyl-10-deazaaminopterin 3tazemetostat 2ruxolitinib 2ixazomib 2duvelisib 2Nivolumab 2Bendamustine Hydrochloride 2venetoclax 1tislelizumab 1thymoglobulin 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Carmustine × 1 year × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡